web analytics
Nimblocity represents commitment to nimble and flexible pharma manufacturing | Velesco Pharma

Nimblocity

 

nimblocity reflects Velesco's nimble processes that result in velocity to the clinic. 

Our nimble processes and focused expertise enables us to overcome even the most challenging drug development obstacles. Our team of pharmaceutical company veterans is responsive, accommodating and eager to help you reach the full potential of your compound, quickly and efficiently.

 

We're committed to getting your pharmaceutical product to the clinic on time. Our size, capacity and expertise allow us to accommodate changes swiftly while maintaining control and quality. 

Nimblocity trademark representing Velesco Pharmaceutical Services’ commitment to be nimble and flexible for pharma manufacturing clients.

News and Events

 

Newly Acquired DEA Analytical Laboratory License.  We are licensed to use schedules 2, 2N, 3, 3N, 4, and 5.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

 

 

New Velesco Pharma clinical manufacturing facility begins operations. Read the press release here.

Lisa Crandall, MS, and Peter Angus, PhD, spoke with Pharmaceutical Technology about the best practices in stability testing.  Read the interview here.

 

Velesco has expanded our analytical facilities in a new Wixom, Michigan location with the help of the Bank of Ann Arbor Technology Industry Group. Read the press release here.

  

CEO Dave Barnes has been published in a new Pharmoutsourcing article on Clinical Trial Materials and Manufacturing

  

1 new job postings! Careers 

  

Velesco's work published 

  Formulation Development & Manufacturing:

Using a Single Provider Reduces Costs & Risk

Read it here.

  

Follow Velesco: 

 LinkedIn IN Icon 25px Google+ Follow VelescoPharma on Twitter  FB FindUsOnFacebook 100

 

734-274-9877